Ramsay Health Care Ltd
ASX:RHC

Watchlist Manager
Ramsay Health Care Ltd Logo
Ramsay Health Care Ltd
ASX:RHC
Watchlist
Price: 39.42 AUD -0.95% Market Closed
Market Cap: AU$9.1B

Ramsay Health Care Ltd
Investor Relations

Ramsay Health Care Ltd, a behemoth in the healthcare sector, sprouted from humble beginnings in a small Australian town, eventually unfolding its reach across the globe. Founded by Paul Ramsay in 1964, the company has grown to become one of the largest private hospital operators worldwide. It runs a vast network of hospitals, day surgery centers, and primary care facilities, welcoming millions of patients through its doors annually. Operating in markets like Australia, Europe, and parts of Asia, Ramsay thrives on the essential and ever-growing demand for quality healthcare services. The company focuses not only on delivering acute care but also engages in multidisciplinary medical and surgical treatments, serving as a critical backbone supporting public health systems straining under demand pressures.

Ramsay Health Care generates its revenue primarily through patient services, the bulk of which comes from hospital admissions, procedures, and ancillary services such as physiotherapy and pharmacy operations. The company has strategically positioned itself in the private healthcare sector, catering to those willing or necessitated to utilize its vast array of medical services when public system waiting times are unavoidably long. Furthermore, it derives additional income through partnerships and joint ventures, bolstering its capability to offer specialized treatments and research initiatives. By continually expanding and optimizing its healthcare facilities, investing in state-of-the-art technology, and maintaining high standards of patient care, Ramsay aims to capitalize on global demographic trends such as aging populations and increasing chronic disease prevalence. Through these strategic endeavors, Ramsay Health Care ensures it remains a vital player in the global health arena, attuned to both clinical advancements and regional health policy changes.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2026
Call Date
Feb 25, 2026
AI Summary
Q2 2026

Strong Australia Performance: Ramsay Healthcare reported robust growth in its Australian hospital business, with revenue from customers up 8.2% and underlying EBIT up 7.3%, driven by higher acuity admissions, strong theater utilization, and improved PHI indexation.

Dividend Increase: The Board declared a fully franked dividend of $0.425 per share, up 6.3%, representing a 60% payout ratio of underlying earnings.

CapEx Guidance Lowered: Full-year CapEx has been revised down to $755–795 million, below previous guidance, reflecting greater capital discipline and a focus on higher-return projects.

Joondalup Mitigation On Track: Operational initiatives have partially offset funding headwinds at Joondalup, including successful efforts to reduce agency usage.

U.K. Headwinds & Strategy: NHS volume and funding pressures persist in the U.K., but Ramsay is focusing on private work, higher acuity cases, and operational efficiencies to offset slower NHS activity.

Elysium Turnaround Progressing: Elysium continues its turnaround with site closures and cost cuts, with further improvements expected under new leadership.

Ramsay Sante Demerger: The proposed in-specie distribution of Ramsay’s 52.8% stake in Ramsay Sante is moving forward, expected to complete by December 2026 and aimed at simplifying group structure.

Steady Outlook: Management expects continued EBIT growth in Australia and ongoing performance improvement initiatives across all regions.

Key Financials
Revenue (Australia, from customers)
8.2%
Hospital Admissions (Australia)
3.1%
Core Surgical Admissions Growth (Australia)
5.7%
Theater Utilization Improvement (Australia)
1.3% increase (12 months rolling)
Underlying EBIT Growth (Group)
7.3%
Underlying NPAT Growth (Group)
8.1%
Dividend per Share
$0.425 per share
Dividend Payout Ratio
60%
Operating Cash Flow
$350 million
Group CapEx Guidance (Full Year)
$755–795 million
Development CapEx (Australia, Full Year)
$170–190 million
Net Debt (Consolidated Group)
$5.1 billion
Funding Group Leverage Ratio
2.22x
Ramsay Sante Leverage
5.3x
Underlying Tax Rate
36% (half), forecast ~35% (full year)
Net Financing Costs (Forecast)
$590–610 million
Dividends Paid Increase
20%
EBIT Margin Improvement (Australia excl. Joondalup)
40 bps improvement
Clinical Trials Activity Growth (Australia)
23%
Other Earnings Calls

Management

Mr. Andrew Smith B.Com., C.A., J.P., M.B.A.
Chief Financial Officer
No Bio Available
Ms. Kelly Hibbins
Group Head of Investor Relations
No Bio Available
Ms. Henrietta Rowe BECON, L.L.B., M.A.I.C.D.
Group General Counsel & Company Secretary
No Bio Available
Ms. Colleen Harris
Group Chief People Officer
No Bio Available
Mr. Andrew Wearne
Group Chief Risk Officer
No Bio Available
Dr. Rachna Gandhi
Group Chief Transformation & Digital Officer
No Bio Available
Ms. Carmel Monaghan
Chief Executive Officer of Ramsay Australia
No Bio Available
Mr. Pascal Roche
CEO of Ramsay Générale De Santé
No Bio Available
Mr. Nick Costa
Chief Executive Officer of Ramsay UK
No Bio Available
Ms. Joy Chamberlain
Chief Executive Officer of Elysium Healthcare
No Bio Available

Contacts

Address
VICTORIA
ST LEONARDS
Level 7, Tower B,, 7 Westbourne Street
Contacts
+61294333444.0
www.ramsayhealth.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett